Soufflé Therapeutics

RNA therapies company using its REMEDY engine to deliver oligonucleotides to specific cells outside the liver.

What they do

Soufflé closed an oversubscribed $135M Series B in October 2026, led by Juvia Group. Its REMEDY (Receptor Mediated Delivery) engine finds internalizing receptors and pairs them with proprietary binders for cell-specific delivery. The funding takes its lead programs in FSHD, heart failure and muscle and metabolic disorders into first clinical studies.

The record

Vertical: Biotech & Therapeutics
Sub-segment: RNA therapies beyond the liver
Product type: Therapeutic
Stage: Series B
Headquarters: Boston, USA
Region: North America
Founded: Not disclosed
Total funding: $135M raised

Notable investors: Juvia Group, TCG Crossover, BB Biotech, Fidelity, Balyasny, Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners, Leaps by Bayer.